Study Summary
This trial will test whether adding olaparib to pembrolizumab will help treat patients with solid tumors that have mutations that affect the Homologous Recombination Repair process.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 12 Secondary · Reporting Duration: Up to ~3 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Olaparib+Pembrolizumab
1 of 1
Experimental Treatment
300 Total Participants · 1 Treatment Group
Primary Treatment: Olaparib · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
How old are they?
18 - 65 | 100.0% |
What site did they apply to?
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0201) | 100.0% |
What portion of applicants met pre-screening criteria?
Met criteria | 100.0% |
- Cannon, Timothy Lewis, MD., Jamie N Randall BA., Ethan S. Sokol PhD., Sonja M. Alexander, Raymond C. Wadlow MD., Arthur A. Winer MD., Daniel M. Barnett MD., Danny L. Rayes BS., Halla S. Nimeiri MD., and Kimberly A. McGregor MD. 2022. “Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of Mcrc Patients with Prolonged OS”. Cancer Treatment and Research Communications. Elsevier BV. doi:10.1016/j.ctarc.2022.100569.
- 2019. "Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04123366.
Frequently Asked Questions
Is this research project presently recruiting participants?
"Affirmative. Information hosted on clinicaltrials.gov indicates that this experiment is presently accepting participants, having first been listed in November 2019 and last updated two years later." - Anonymous Online Contributor
Are there any precedent investigations into the effects of Olaparib?
"Olaparib was initially explored in 2005 at Research Site. Since then, 314 clinical trials have concluded and 1114 are currently underway; San Francisco is the epicentre for many of these investigations." - Anonymous Online Contributor
What is the size of the cohort that is being monitored for this experiment?
"Affirmative. The information published on clinicaltrials.gov suggests that this scientific experiment is currently recruiting for 300 participants across 18 sites, with the first post appearing November 18th 2019 and latest update completed November 29th 2022." - Anonymous Online Contributor
Is this pioneering clinical trial a first-time endeavor?
"Since 2005, when the initial research was sponsored by AstraZeneca and included 98 patients, Olaparib has gone on to receive Phase 1 drug approval. Nowadays, there are 1114 clinical studies being conducted across 66 nations in 3058 cities." - Anonymous Online Contributor
Are there numerous health care centers trialing this protocol domestically?
"Currently, 18 clinical trial sites are recruiting patients for this medical study. These locations span from San Francisco to Birmingham and Fairfax as well as several other cities. To limit the need for travel, we suggest selecting a site close by when enrolling in the trial." - Anonymous Online Contributor
How detrimental is Olaparib for patients?
"Olaparib has been assessed as a 2 on the safety scale, given that Phase 2 only offers limited evidence of its security but no proof of efficacy." - Anonymous Online Contributor
In what capacity is Olaparib generally employed?
"Olaparib is commonly utilized to treat inoperable melanoma, as well as high risk of recurrence cases and microsatellite instability conditions." - Anonymous Online Contributor